HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial in AML, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine
HiberCell Announces FPD in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with ccRCC
HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366
NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced...
HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan)
HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of HC-5404 and Maps Forward Path as Monotherapy and in Combinations
BOSTON, May 22, 2023 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced dosing of...
HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML)
NEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, today announced two clinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting taking place November 8-12, 2022 in Boston, MA.